Navigation Links
MetaStat to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22, 2013
Date:1/18/2013

MONTCLAIR, N.J., Jan. 18, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), ("MetaStat" or the "Company"), a life science company focused on understanding and treating systemic metastasis, today announced that the Company will be presenting at the NINE 2013 - Noble Financial Capital Markets' Ninth Annual Equity Conference held at the Hard Rock Hotel & Casino, Hollywood, Florida, on Tuesday, January 22, 2013 at 4:30 p.m. Eastern Time.  Dr. Oscar Bronsther , Chief Executive Officer and Chief Medical Officer, will host the presentation.

A live audio and high-definition video webcast of MetaStat's presentation and a copy of the presentation materials will be available on the Noble Financial websites: www.noblefcm.com, or www.nobleresearch.com/nine/home.htm.

About MetaStat, Inc.
MetaStat's proprietary platform technologies are the result of over 15 years of collaboration involving four scientific/academic institutions, which enabled us to characterize the behavior, mechanics and genetics of metastatic cancer cells.

Our MetaSite Breast™ and MenaCalc™ diagnostic product lines are designed to accurately predict the probability of cancer metastasizing. They are intended to allow clinicians to better "customize" cancer treatment decisions by positively identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies. Furthermore, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid epithelial cancers, including breast, prostate, lung and colorectal, which account for over 50% of all new cancer cases in the U.S. each year. As such, we believe our diagnostic prod
'/>"/>

SOURCE MetaStat, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
2. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
3. MetaStat, Inc. Announces Allowance of Patent Claims
4. Can Cannabidiol (CBD) Fight Metastatic Cancer? According to the latest research the answer is yes.
5. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
6. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
10. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
11. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015 - Development of a ... the VOLVOX Platform - To be Presented on Tuesday, ...  Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal ... Sunday, Apr 19, 1:00 PM EST Invictus ... today announced that the company,s novel computational platform technology ...
(Date:4/20/2015)... MIAMI (PRWEB) April 20, 2015 ... attend The Aesthetic Meeting 2015, an annual gathering of ... Alfredo Hoyos, M.D., is scheduled to introduce the company’s ... injection techniques with adipose-derived stem cell techniques. , ... that concern patients in the aesthetic field, including facial ...
(Date:4/17/2015)... PA (PRWEB) April 17, 2015 ... a leader in regulatory data management, preparation, and submission ... today the availability of a new Lot Distribution Report ... are required to remain compliant with the FDA’s new ... by the FDA to monitor the volume and timing ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
Breaking Biology Technology:Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... - Conference Call to Discuss Results to Be Held at ... Incorporated,s (Nasdaq: VPHM ) first quarter financial results ... 29, 2009 before the open of the U.S. financial markets.The ... at 9:00 a.m. Eastern Time on the same day. ...
... Human Tissue Collection and Specimen Management Provide FocusMEMPHIS, ... the physician partners of Accelerated Community Oncology Research ... (USA), has begun acquiring human tissue samples for ... World BioBank supports biomarker storage in conjunction with ...
... Calif., April 22 Metabolex, Inc., a biopharmaceutical company ... therapeutics for the treatment of diabetes and related metabolic ... to its Board of Directors. Mr. von Emster currently ... November 2000 to March 2009, Mr. von Emster was ...
Cached Biology Technology:ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2World BioBank(TM) Launch Benefits Advanced Medical Research 2World BioBank(TM) Launch Benefits Advanced Medical Research 3Metabolex Announces Election of Kurt von Emster to Board of Directors 2
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... that freezing kidney tumors through percutaneous cryoablation shows promise ... Their early findings showing short-term success in more ... this month’s issue of Radiology. , The standard treatment ... of a long-term cure. For some patients, surgery ...
... Medicine has helped confirm the reliability of a new ... long-promised era of personalized medicine based on each individual's ... five sites that helped determine that the genetic test ... developing cirrhosis from chronic hepatitis C infection. That means ...
... A study of eight hospitals in Peru has shown ... double that of mechanically ventilated negative-pressure rooms and 18 ... , The researchers, led by Rod Escombe from ... ventilated clinical rooms such as respiratory isolation rooms, TB ...
Cached Biology News:Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3
...
... Modules Highly efficient ... cloning into advanced λ ... For flexibility ... Systems, the modules of ...
... to siRNA library screening, optimal ... identified and verified for each ... CellReady siRNA Transfection Optimization Kit, ... optimizing transfection conditions in 96 ...
...
Biology Products: